NK cell turnover and division during infection of mice with lymphocytic choriomeningitis virus (LCMV) was examined. Treatments with hydroxyurea (HU), a drug specific for cells synthesizing DNA, had no effect on control spleen NK cells, but significantly reduced NK cell-mediated lysis in LCMV-infected mice. When HU was administered at 9 and 2 hr before spleen cell harvest, the augmented lysis mediated by NK cells isolated from LCMV-infected mice was only 40% of that mediated by NK cells isolated from LCMV-infected untreated mice. Spleen cells that had been pulse-labeled with [3H]thymidine were used in a single cell assay with autoradiography to detect lysis mediated by blast cells. HU eliminated blast-NK cells; 34% of activated NK cell killing was mediated by blast cells, whereas less than 12% of the reduced NK cell activity after HU treatments was blast cell-mediated. The NK cells activated in vivo had lower densities than control NK cells. Although the total cell yields from control spleens and spleens on day 3 post-infection with LCMV were similar, low density Percoll gradient fractions from the day 3 spleen cell preparations contained three times as many cells as equivalent fractions from control populations. The same low density fractions were enriched in NK cell activity and in blast-NK cells. Activated spleen cell populations also contained increased numbers of large granular lymphocytes. These data indicate that NK cells have increased turnover rates during viral infection, that this increase in turnover is accompanied by NK cell division, and that this results in increases in the numbers of NK cells.
Download full-text PDF |
Source |
---|
Background: The autophagy lysosomal pathway (ALP) and the ubiquitin-proteasome system (UPS) are key proteostasis mechanisms in cells, which are dysfunctional in AD and linked to protein aggregation and neuronal death. Autophagy is over activated in Alzheimer's disease brain whereas UPS is severely impaired. Activating autophagy has received most attention, however recent evidence suggests that UPS can clear aggregate proteins and a potential therapeutic target for AD and protein misfolding diseases.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is the most common cause of dementia worldwide. It is characterized by dysfunction in the U1 small nuclear ribonucleoproteins (snRNPs) complex, which may precede TAU aggregation, enhancing premature polyadenylation, spliceosome dysfunction, and causing cell cycle reentry and death. Thus, we evaluated the effects of a synthetic single-stranded cDNA, called APT20TTMG, in induced pluripotent stem cells (iPSC) derived neurons from healthy and AD donors and in the Senescence Accelerated Mouse-Prone 8 (SAMP8) model.
View Article and Find Full Text PDFBackground: Immunotherapy of Alzheimer's disease (AD) is a promising approach to reducing the accumulation of beta-amyloid, a critical event in the onset of the disease. Targeting the group II metabotropic glutamate receptors, mGluR2 and mGluR3, could be important in controlling Aβ production, although their respective contribution remains unclear due to the lack of selective tools.
Method: 5xFAD mice were chronically treated by a brain penetrant camelid single domain antibody (VHH or nanobody) that is an activator of mGluR2.
Alzheimers Dement
December 2024
Columbia University Irving Medical Center, New York, NY, USA.
Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.
View Article and Find Full Text PDFBackground: Our previous study identified that Sildenafil (a phosphodiesterase type 5 [PDE5] inhibitor) is a candidate repurposable drug for Alzheimer's Disease (AD) using in silico network medicine approach. However, the clinically meaningful size and mechanism-of-actions of sildenafil in potential prevention and treatment of AD remind unknown.
Method: We conducted new patient data analyses using both the MarketScan® Medicare with Supplemental database (n = 7.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!